Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

LintonPharm Starts China Trial of Candidate for Bladder Cancer

publication date: Apr 13, 2021

LintonPharm, a Guangzhou biopharma, was approved to start a China Phase I/II clinical trial of catumaxomab to treat recurrent Non-Muscle-Invasive Bladder Cancer (NMIBC). The trial will enroll patients whose tumors have recurred due to Bacillus Calmette-Guerin (BCG) vaccine failure. In 2020, LintonPharm started a China Phase III trial of catumaxomab. an immunotherapy, in patients with advanced gastric cancer. LintonPharm develops innovative T cell engaging bispecific antibodies, aiming to turn malignant cancers into manageable or curable diseases. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital